What's Happening?
The biopharma industry is experiencing significant regulatory uncertainty due to changes at the FDA, affecting acquisition strategies and deal structures. Over the past eighteen months, the FDA has faced instability driven by leadership turnover, political
scrutiny, and shifts in regulatory priorities. These changes have raised questions about consistency in regulatory decision-making and enforcement, particularly impacting biologics, gene therapies, and vaccines. The Center for Biologics Evaluation and Research (CBER) has seen leadership changes, altering guidance priorities and scientific frameworks, which complicates the approval process for certain therapies. This uncertainty affects deal timing and valuations, making it challenging to value early and clinical stage assets. Despite these challenges, deal activity remains robust, with $47 billion in acquisitions across 19 deals in the first quarter of 2026.
Why It's Important?
The regulatory uncertainty at the FDA has significant implications for the biopharma industry, affecting how companies plan development and transaction timelines. The inconsistency in regulatory decision-making can lead to increased risk for life sciences companies, impacting their strategic initiatives and financial planning. As companies navigate these uncertainties, they are adopting mitigation strategies such as pre-acquisition relationships, milestone-based payments, and contingent value rights tied to FDA outcomes. These strategies help manage regulatory risk and bridge valuation gaps, but they also introduce legal complexities. The ongoing uncertainty may influence the industry's approach to acquisitions, potentially favoring late-stage assets and creative deal structures to mitigate risks.
What's Next?
As the biopharma industry continues to adapt to FDA regulatory uncertainties, companies are likely to focus on building relationships with future targets through licensing and collaboration arrangements. Acquirers may prioritize late-stage assets and employ creative deal structures to manage risks and bridge valuation gaps. The industry may also see a shift towards higher upfront payments in competitive transaction environments, as evidenced by recent trends. While mega-deals have been less common, smaller acquisitions are expected to continue as companies seek to support their strategic initiatives amidst regulatory challenges.
